Chembio Diagnostics ROE 2006-2019 | CEMI

Current and historical return on equity (ROE) values for Chembio Diagnostics (CEMI) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Chembio Diagnostics ROE for the three months ending March 31, 2019 was -36.34%.
Chembio Diagnostics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2019-03-31 $-0.01B $0.03B -37.74%
2018-12-31 $-0.01B $0.03B -32.32%
2018-09-30 $-0.01B $0.02B -35.44%
2018-06-30 $-0.01B $0.02B -32.43%
2018-03-31 $-0.01B $0.02B -35.82%
2017-12-31 $-0.01B $0.01B -46.67%
2017-09-30 $-0.01B $0.02B -50.00%
2017-06-30 $-0.01B $0.02B -52.17%
2017-03-31 $-0.02B $0.02B -95.24%
2016-12-31 $-0.01B $0.02B -82.54%
2016-09-30 $-0.01B $0.02B -68.75%
2016-06-30 $-0.01B $0.01B -58.06%
2016-03-31 $-0.00B $0.02B -11.11%
2015-12-31 $-0.00B $0.02B -16.22%
2015-09-30 $-0.00B $0.02B -10.53%
2015-06-30 $-0.00B $0.02B -10.26%
2015-03-31 $-0.00B $0.02B -5.06%
2014-12-31 $0.00B $0.02B 0.00%
2014-09-30 $0.00B $0.02B 0.00%
2014-06-30 $0.00B $0.02B 5.00%
2014-03-31 $0.00B $0.02B 5.00%
2013-12-31 $0.00B $0.02B 5.41%
2013-09-30 $0.00B $0.02B 5.88%
2013-06-30 $0.00B $0.02B 0.00%
2013-03-31 $0.00B $0.01B 0.00%
2012-12-31 $0.00B $0.01B 0.00%
2012-09-30 $0.01B $0.01B 46.15%
2012-06-30 $0.01B $0.01B 52.17%
2012-03-31 $0.01B $0.01B 63.16%
2011-12-31 $0.01B $0.01B 77.42%
2011-09-30 $0.00B $0.01B 32.00%
2011-06-30 $0.00B $0.01B 36.36%
2011-03-31 $0.00B $0.01B 60.00%
2010-12-31 $0.00B $0.01B 70.59%
2010-09-30 $0.00B $0.00B 28.57%
2010-06-30 $0.00B $0.00B 30.77%
2010-03-31 $0.00B $0.00B 0.00%
2009-12-31 $0.00B $0.00B 0.00%
2009-09-30 $-0.00B $0.00B -40.00%
2009-06-30 $-0.00B $0.00B -40.00%
2009-03-31 $-0.00B $0.00B -36.36%
2008-12-31 $-0.00B $0.00B -61.54%
2008-09-30 $-0.01B $0.00B -171.43%
2008-06-30 $-0.01B $0.00B -186.67%
2008-03-31 $-0.01B $0.00B -188.24%
2007-12-31 $-0.01B $0.00B -177.78%
2007-09-30 $-0.01B $0.00B -120.00%
2007-06-30 $-0.01B $0.01B -155.56%
2007-03-31 $-0.01B $0.01B -215.38%
2006-12-31 $-0.01B $0.01B -355.56%
2006-09-30 $-0.01B $0.00B -600.00%
2006-06-30 $-0.01B $0.00B -500.00%
2006-03-31 $-0.01B $0.00B -285.71%
2005-12-31 $-0.01B $0.00B -280.00%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.098B $0.033B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $147.856B 28.70
Medtronic (MDT) Ireland $133.874B 19.12
Stryker (SYK) United States $76.669B 27.36
Boston Scientific (BSX) United States $59.033B 28.30
Baxter (BAX) United States $41.839B 26.37
EssilorLuxottica Societe Anonyme (ESLOY) France $29.060B 0.00
Coloplast (CLPBY) Denmark $25.618B 40.90
Zimmer Biomet Holdings (ZBH) United States $24.965B 16.04
Lonza Group Ag (LZAGY) Switzerland $24.947B 0.00
Terumo (TRUMY) Japan $23.393B 26.90
Smith & Nephew SNATS (SNN) United Kingdom $19.274B 0.00
ResMed (RMD) United States $17.745B 33.90
Canopy Growth (CGC) Canada $12.161B 0.00
Sunny Optical Technology (SNPTF) China $12.027B 0.00
Bio-Rad Laboratories (BIO) United States $9.308B 49.34
William Demant Holdings (WILYY) Denmark $7.651B 0.00
Insulet (PODD) United States $7.203B 524.78
Aurora Cannabis (ACB) Canada $7.109B 70.10
Perrigo (PRGO) Ireland $7.004B 11.84
Hill-Rom Holdings (HRC) United States $6.993B 21.20
GN STORE NORD (GNNDY) Denmark $6.409B 32.73
Haemonetics (HAE) United States $6.325B 51.63
ICU Medical (ICUI) United States $5.135B 30.64
GW Pharmaceuticals (GWPH) United Kingdom $5.057B 0.00
Neogen (NEOG) United States $3.349B 54.45
NuVasive (NUVA) United States $2.982B 24.36
Hutchison China MediTech (HCM) China $2.925B 0.00
Agios Pharmaceuticals (AGIO) United States $2.711B 0.00
National Vision Holdings (EYE) United States $2.420B 51.57
Quidel (QDEL) United States $2.309B 23.96
Cardiovascular Systems (CSII) United States $1.598B 917.80
Aphria (APHA) $1.579B 0.00
Phibro Animal Health (PAHC) United States $1.229B 18.41
AtriCure (ATRC) United States $1.218B 0.00
VAREX IMAGING (VREX) United States $1.187B 25.19
Lantheus Holdings (LNTH) United States $1.089B 28.93
NanoString Technologies (NSTG) United States $1.056B 0.00
PetIQ (PETQ) United States $0.994B 24.14
MacroGenics (MGNX) United States $0.777B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.765B 21.47
Cerus (CERS) United States $0.758B 0.00
Quanterix (QTRX) United States $0.753B 0.00
Omeros (OMER) United States $0.750B 0.00
TG Therapeutics (TGTX) United States $0.698B 0.00
LeMaitre Vascular (LMAT) United States $0.572B 27.71
Surmodics (SRDX) United States $0.543B 78.88
OraSure Technologies (OSUR) United States $0.531B 24.43
Meridian Bioscience (VIVO) United States $0.476B 14.56
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.404B 0.00
Vapotherm (VAPO) United States $0.345B 0.00
Utah Medical Products (UTMD) United States $0.320B 22.13
BioLife Solutions (BLFS) United States $0.304B 95.24
Zynex (ZYXI) United States $0.250B 25.67
Bovie Medical (APYX) United States $0.236B 0.00
Cytosorbents (CTSO) United States $0.227B 0.00
Owens & Minor (OMI) United States $0.198B 4.20
Chimerix (CMRX) United States $0.188B 0.00
United Health Products (UEEC) United States $0.175B 0.00
Rockwell Medical (RMTI) United States $0.170B 0.00
Female Health (VERU) United States $0.146B 0.00
Fonar (FONR) United States $0.139B 7.33
United-Guardian (UG) United States $0.094B 20.65
InfuSystems Holdings (INFU) United States $0.090B 0.00
Surface Oncology (SURF) United States $0.075B 0.00
Trinity Biotech (TRIB) Ireland $0.060B 20.75
Oramed Pharmaceuticals (ORMP) United States $0.058B 0.00
MRI INTERVENTNS (MRIC) United States $0.052B 0.00